A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

To join this study, you would need to be 18 years old or older and have a Body Mass Index (BMI) of 35 or above, which is a measure that indicates obesity. You would also need to have a history of heart or blood vessel disease, such as having had a heart attack, stroke, or a condition affecting the blood flow to your legs. Additionally, you should have tried to lose weight through dieting at least once before, without success.

There are also some reasons why you might not be able to join. For example, if you've recently had a serious heart event, like a heart attack or stroke, within the last three months, or if you've had major heart surgery during that time. You also couldn't join if you've taken weight-loss medicines (even some over-the-counter ones) in the last three months, or if you've had major weight-loss surgery or have plans to have one. Significant weight changes (more than 5 kg or about 11 pounds) in the last three months would also make you ineligible. People with Type 1 diabetes, a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma or MEN-2), or a history of pancreatitis would also not be able to participate.

If you decide to take part in this study, it would last for about two years (113 weeks). You would have regular visits to the clinic where you would have various assessments. This would likely include physical examinations, blood tests, and other checks to monitor your health and how the study medicine is affecting you. You would be given either the new medicine (retatrutide) or a placebo (a dummy medicine) to take once a week. The research team would explain exactly how and when to take your study medicine. After the main treatment period, there will be a follow-up period to ensure your continued well-being. All study-related care and medicines would be provided at no cost, and you would be fully supported throughout the process.